

ALPHADIA ANTI È PCA (RS) IgG Assay

IMMUNOFLUORESCENCE ASSAY
FOR THE DETECTION
OF ANTI - PARIETAL IgG
ANTIBODIES IN HUMAN SERUM

CAT # AD PRS48 48 TESTS
CAT # AD PRS96 96 TESTS

FOR IN VITRO DIAGNOSTIC USE
CONS : 2 - 8°C

ALPHADIA sa/nv

DIAGNOSTIC PRODUCTS
AVENUE VESALE 26 - B1300 WAVRE
BELGIUM

TEL : 32 (0) 10 24 26 49

FAX : 32 (0) 10 24 55 99

contact@alphadia.be

INTRODUCTION

Gastric autoimmune disease have been classified into Type A and Type B gastritides, based on the morphological changes of the fundus and antral portion of the stomach. Patients with antibodies to parietal cells (PCA) or intrinsic factor (or both) have atrophy of the fundal mucosa (Type A) and a very high rate of pernicious anemia, often associated with other autoimmune endocrine disorders. A positive PCA in the presence of a megaloblastic anemia makes pernicious anemia a probable diagnosis. In type B gastritis, PCA is lacking and there is no association with pernicious anemia or other autoimmune endocrine disorders.

The indirect immunofluorescent method is the test of choice for detecting PCA and is more sensitive than the CF method. The gastric mucosa of rat or mouse stomach is utilized for PCA detection in this test system.

The incidence of PCA in patients with pernicious anemia is 93%. Conditions other than pernicious anemia may give positive PCA results : atrophic gastritis, diabetes mellitus, Hashimoto's disease, gastric ulcer, thyrotoxicosis , myasthenia gravis, iron deficiency anemia, idiopathic Addison's disease, primary myxedema, Sjogren's syndrome and rheumatoid arthritis. In the normal population, PCA varies from 2% in the under 20 age group to 16% in the over 60 age group.

PCA should be included in a differential work-up of patients with megaloblastic anemia since 93% of patients with pernicious anemia will be detected.

PRINCIPLES

The Parietal Cell Antibodies reaction involves circulating antibodies to intercytoplasmic components of the parietal cell. PCA is organ specific, but not species specific. However, anti-mitochondrial antibody (MA) is not organ specific and will react with parietal cells and resemble PCA fluorescence. Therefore, in order to differentiate a true PCA from an MA, the specimen showing PCA fluorescence should be tested on rat or mouse kidney section. A true PCA will not show renal tubular fluorescence while an MA will react with both kidney tubules and parietal cells.

Recent studies have demonstrated a potential pitfall in the detection of PCA. Smooth muscle antibodies (SMA) from patients with chronic acute hepatitis (CAH) bind to gastric parietal cells in an immunofluorescent pattern indistinguishable from PCA. Therefore, in order to differentiate a true PCA from a SMA, the specimen showing PCA fluorescence should be checked for a positive staining in the muscularis mucosa. A true PCA will not show the stomach muscularis mucosal fluorescence, but a SMA may react with both muscularis mucosa and parietal cells.

Recent studies have demonstrated a potential pitfall in the detection of PCA. Smooth muscle antibodies (SMA) from patients with chronic acute hepatitis (CAH) bind to gastric parietal cells in an immunofluorescent pattern indistinguishable from PCA. Therefore, in order to differentiate a true PCA from a SMA, the specimen showing PCA fluorescence should be checked for a positive staining in the muscularis mucosa. A true PCA will not show the stomach muscularis mucosal fluorescence, but a SMA may react with both muscularis mucosa and parietal cells.

In order to facilitate this type of differentiation, slides are available containing three sections per well, i.e.; monkey thyroid/rat stomach/rat kidney which allows for immediate differentiation of thyroid reactions, as well as PCA from non-organ specific MA reactions in one well. PCA is primarily IgG, but may occasionally be found in the IgM immunoglobulin fractions.

The primary reaction involves circulating PCA antibodies present in the patient's serum which attach to their homologous parietal cell antigens. This occurs during the incubation period while the serum covers the antigen surface. A secondary reaction then follows a rinsing period which removes all unbound human antibody. The reagent used in the secondary reaction is a fluorescein labelled anti-human globulin conjugate. The antigen surface is then thoroughly rinsed free of unbound conjugate and viewed under an appropriate fluorescence microscope. Bright granular cytoplasmic fluorescence limited to the parietal cells of

the rat or mouse stomach gastric mucosa indicates a positive result. Fluorescence of the other cellular antigens such as nuclei, smooth muscle, connective tissue or chief cells should not be reported as positive PCA.

MATERIALS PROVIDED

Storage and stability of components

1. FITC Conjugate N° CGER2 - 3 ml with Evans blue counterstain is to be stored at 2-8°C upon receipt. The conjugate is stable at this temperature until expiration date on the vial label. This reagent contains antibodies which will react with the human IgG, IgM and IgA immunoglobulin classes.

2. The Antigen slides of rat or mouse stomach sections must be stored at 2-8°C or lower upon receipt. Check label for specific expiration date.

3. PCA Positive control N°PCPC - 1 ml should be stored at 2-8°C upon receipt. Check label for specific expiration date.

4. Universal negative control N° NC05 - 1 ml should be stored at 2-8°C or lower upon receipt. Check label for specific expiration date.

5. Buffer pack N°PBS1 - Phosphate Buffer Saline is stable at room temperature storage for 5 years. The reconstituted buffer does not contain preservatives and should be stored at 2-8°C. Care should be taken to avoid contamination.

6. Mounting medium N° TMM3 - 3ml is stable when stored at 2-8°C. Check label for specific expiration date.

NOTE : All kit components are available separately.

Additional materials required but not provided

Test tubes and rack or microtiter system

Disposable pipettes

Staining dish and slide forceps

Moisture chamber

Distilled water

Fluorescence microscope

Paper towels

Reagent preparation

Buffer pack.

Rehydrate buffer with 1 liter of sterile distilled water.

SPECIMEN COLLECTION

Serological specimens should be collected under aseptic conditions. Hemolysis is avoided through prompt separation of the serum from the clot. Serum should be stored at 2-8°C if it is to be analyzed within a few days. Serum may be held for 3 to 6 months by storage at -20°C or lower. Lipemic and strongly hemolytic serum should be avoided. When specimens are shipped at ambient temperature, addition of a preservative such as 0.01% (thimerosal) or 0.095% sodium azide is strongly recommended.

TEST INSTRUCTION

Screening : dilute test serums 1:20 in PBS.

Titration : set up doubling dilutions of serum starting at 1:20 (i.e 1:20, 1:40, 1:80, 1:160...)

1. Once slides reach room temperature tear slide envelope at notch. Carefully remove the slide and avoid touching the antigen areas. The slide is now ready to use.

2. Place a drop of diluted serum (20-30µl) and controls over the antigen wells.

3. Place slide with patient's serum and controls in a moist chamber for 30 minutes at room temperature (approximately 24°C).

4. Remove slide from moisture chamber and tap the slide on its side to allow the serum to run off onto a piece of paper towel. Using a wash bottle, gently rinse remaining sera from slide being careful not to aim the rinse stream directly on to the well.

5. Wash in PBS for five minutes. Repeat using fresh PBS.

6. Place a blotter on the lab table with absorbent side up. Remove slide from PBS and invert so that tissue side faces absorbent side of blotter. Line up wells to blotter holes. Place slide on top of blotter. Do not allow tissue to dry. Wipe back of slide with dry lint free paper towel. Apply sufficient pressure to slide while wiping to absorb buffer.

7. Deliver 1 drop (25-30µl) of conjugate per antigen well. Repeat steps 3-6.

8. Place 4-5 drops of mounting medium on slide.

9. Apply a 22 x 70 mm coverslip. Examine the slide under a fluorescent microscope. Note : To maintain fluorescence, store mounted slide in a moisture chamber placed in the dark refrigerator.

QUALITY CONTROL

1. Positive and negative serum controls must be included in each day's testing to confirm reproductibility, sensitivity and specificity of the test procedure.

2. The negative serum control should result in little (+) or no fluorescence. If this control shows bright fluorescence, either the control, antigen, conjugate or technique may be at fault.

3. The positive serum control should result in bright 3+ to 4+ fluorescence. If this control shows little or no fluorescence, either the control, antigen, conjugate or technique may be at fault.

4. In addition to positive and negative serum controls, a PBS control should be run to establish that the conjugate is free from nonspecific staining of the antigen substrate. If the antigen shows bright fluorescence in the PBS control repeat using fresh conjugate. If the antigen still fluoresces, either the conjugate or antigen may be at fault.

RESULTS

Pernicious anemia is megaloblastic anemia. A positive PCA test from a patient with a megaloblastic anemia helps establish a presumptive diagnosis of pernicious anemia or pernicious anemia associated with a second disease. Additional confirming tests for pernicious anemia are : antibodies to intrinsic factor, vitamin B12 absorption or serum vitamin B12 activity. A key factor in differentiating between pernicious anemia and simple atrophic gastritis is the lack of antibody to intrinsic factor in atrophia gastritis.

On the basis of PCA alone, one may assume some form of atrophic gastritis which may or may not be related to pernicious anemia. PCA are generally

associated with some degree of hypochlorhydria.

In addition to its diagnostic potential, PCA testing is helpful in screening genetically determined high risk groups (i.e.; relatives of thyroid patients and pernicious anemia patients) for asymptomatic chronic atrophic gastritis and for early recognition of atrophic gastritis and pernicious anemia.

A positive result is observed as bright granular cytoplasmic fluorescence of parietal cells of the rat or mouse gastric mucosa. Fluorescence of other cellular antigens such as nuclei, smooth muscle, or connective tissue should not be reported as positive PCA.

TITER INTERPRETATION

The titer is the highest dilution of the patient's serum showing weak (1+) fluorescence of the parietal cells.

The clinical significance of the PCA titer has no relation to the severity or duration of the disease state. Thus, one cannot predict or assume on the basis of PCA titer alone the degree of impaired secretion of intrinsic factor or the extent of histopathologic changes.

Immunofluorescence detection of autoimmune disease. Immunology Series N°7, U.S.D.H.E.W. CDC. 1976,p66).

LIMITATIONS OF PROCEDURE

1. No diagnosis should be based upon a single serologic test result, since various host factors must be taken into consideration.

PRECAUTIONS

1. All human components have been tested by radioimmunoassay for HBsAg and HTLVIII/LAV by an FDA approved method and found to be negative. Not repeatedly reactive. However, this does not assure the absence of HBsAg or HTLVIII/LAV. All human components should be handled with appropriate care.

2. The sodium azide (0.095%) included in the controls and conjugate is toxic if ingested.

3. Do not use components beyond their expiration date.

4. Follow the procedural instructions exactly as they appear in this insert to insure valid results.
5. For in vitro diagnostic use.
6. Handle slides by the edges since direct pressure on the antigen wells may damage the antigen.
7. Once the procedure has started do not allow the antigen in the wells to dry out. This may result in false negative test results, or unnecessary artifacts.

BIBLIOGRAPHY

1. Strickland, R.G., and Mackay, I.R., "A reappraisal of the nature and significance of chronic atrophic gastritis." *AM. J. Diag. Dis.*, 18: 426-440, 1973.
2. Glass, G.B.J., "Immunology of atrophic gastritis," *N.Y. State J. Med.*, 77: 1697-1706, 1977.
3. Strickland, R.G. and Mackay, I.R., *Op cit.*
4. Vandelli, Bottazzo, G.F., Doniach, D. and Franchesi, F., "Autoantibodies to gastrin-producing cells in antral (type B) chronic gastritis," *New Eng. J. of Med.*, Vol. 300, No. 25: 1406-1410, 1979.
5. Coredig, R. and Toh, B.H., "Reaction of human smooth muscle autoantibody with gastric parietal cells: a pitfall in the diagnosis of parietal cell autoantibody.: *J. Clin. Patho.*, 30:666-670, 1977.
6. Glass, B.G.J., :Gastric Intrinsic Factor and other Vitamin B12 Binders, *Biochemistry, Physiology, Pathology and Relation to Vitamin B12 Metabolism.*: Georg Thieme Veriag, Stuttgart, 1974.
7. O'Donoghue et al, "Gastric lesion in dermatitis herpetiformis." *Gut*, 17:185-188, 1976.



ALPHADIA sa/nv
DIAGNOSTIC PRODUCTS
AVENUE VESALE 26 -
B1300 WAVRE
BELGIUM
TEL : 32 (0) 10 24 26 49
FAX : 32 (0) 10 24 55 99
contact@alphadia.be

